Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIN-112
- Development stage
- Preclinical
- Lead developer
- Kinimmune
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
KIN-112 is an investigational, localized cancer immunotherapy being developed by Kinimmune. It is a tissue-retentive complex consisting of a proprietary, next-generation glatiramoid peptide complexed with a CpG Toll-like receptor 9 (TLR9) agonist. Designed for intratumoral administration, KIN-112 is engineered to concentrate innate immune activation directly within the tumor microenvironment, thereby limiting systemic exposure and associated toxicities while promoting a robust, localized antitumor immune response. The program is currently in the lead optimization stage of preclinical development for the treatment of solid tumors.
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on KIN-112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIN-112.